Trial Profile

A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taniraleucel (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; Therapeutic Use
Acronyms CYNKCOVID
Sponsors Celularity

Most Recent Events

17 Jun 2021 Status changed from recruiting to active, no longer recruiting.
14 Apr 2021 According to a Celularity media release, data from this trial will be presented at American Association for Cancer Research (AACR) Annual Meeting 2021.
10 Apr 2021 Results (n=6; till date) of phase I portion of this trial presented at the 112th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com